Nat Rev Drug Discov. 2025 Feb 3. IF: 122.7Novel strategies to manage CAR-T cell toxicity.www.nature.com/articles/s41573-024-01100-5 Nat Med. 2025 Feb 3. IF: 58.7Immunotherapy boosts responses in hormone receptor-positive breast cancers.www.nature.com/articles/s41591-024-03441-5 Nat Med. 2025 Feb 3. IF: 58.7Clinical applications of human organoids.www.nature.com/articles/s41591-024-03489-3 Lancet Oncol. 2025 Feb 3. IF: 41.6UK's National Cancer Plan needs to be radical, accountable, and deliverable.www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00033-6 Lancet Digit Health. 2025 Feb 3. IF: 23.8Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study.www.thelancet.com/journals/landig/article/PIIS2589-7500(24)00267-X Nat Commun. 2025 Feb 3;16(1):1279. IF: 14.7Micro Immune Response On-chip (MIRO) models the tumour-stroma interface for immunotherapy testing.www.nature.com/articles/s41467-025-56275-1 Nat Commun. 2025 Feb 3;16(1):1291. IF: 14.7Early tolerance and late persistence as alternative drug responses in cancer.www.nature.com/articles/s41467-024-54728-7 Angiogenesis. 2025 Feb 3;28(2):13. IF: 9.2Clioquinol inhibits angiogenesis by promoting VEGFR2 degradation and synergizes with AKT inhibition to suppress triple-negative breast cancer vascularization.link.springer.com/article/10.1007/s10456-024-09965-1 J Natl Cancer Inst. 2025 Feb 3. IF: 9.9Changes in time-to-treatment initiation for breast, nonsmall cell lung, Colon, or rectal cancers throughout the COVID-19 pandemic in the United States.www.academic.oup.com/jnci/article/7997270
